IDEV Technologies Announces FDA 510(k) Clearance for SUPERA VERITAS(TM)

New SUPERA(R) Delivery System Improves Procedure Predictability and Stent Performance

WEBSTER, Texas, November 3, 2010 - IDEV Technologies, Incorporated (IDEV), an innovative leader in the
development and commercialization of minimally invasive medical technologies,
today announced U.S. Food and Drug Administration (FDA) 510(k) clearance to
market the SUPERA VERITAS Transhepatic Biliary System.

SUPERA VERITAS is the next-generation delivery system for IDEV's unique
SUPERA(R) wire interwoven nitinol stent, currently cleared in the U.S. for
palliative treatment of biliary strictures produced by malignant neoplasms.
The SUPERA VERITAS system is also approved for use in the ongoing
FDA-approved IDE trial in the U.S. for treatment of peripheral arterial
disease of the superficial femoral artery (SFA). The FDA 510(k) clearance
notification was dated October 5, 2010.

"Clearance of the SUPERA VERITAS system represents the culmination of a
strong effort to respond to customer needs," explained Christopher M. Owens,
President and CEO of IDEV. "The result is an innovative system that we
believe provides us with a significant competitive advantage, and may
represent a paradigm shift in how patients are treated."

The new device provides easier deployment of the Supera stent compared to
earlier systems, eliminating multiple steps previously required for
preparation and delivery. More importantly, the new system allows operators
to place the stent more precisely than before.

"I've been deploying the SUPERA stent now for over a year. The high
radial force of the stent is particularly suited for biliary strictures. The
introduction of the SUPERA VERITAS system is a great complement to an
outstanding stent," stated Mark Garcia, MD, Chief of Interventional Radiology
at Christiana Care Health System in Wilmington, Delaware.

Gino Sedillo, MD, FACC of Bradenton Cardiology Center in Bradenton,
Florida, is an investigator in the SFA trial. He commented, "I've seen the
SUPERA VERITAS system demonstrated, and was able to use it myself during a
visit to Park Hospital in Leipzig, Germany. The delivery steps have not only
been greatly simplified, but there is also improved reliability and
predictability of stent placement. I look forward to incorporating the new
delivery system into the ongoing prospective trial."

Don Jacobs, MD, a vascular surgeon at St. Louis University Hospital in
St. Louis, Missouri, was asked to provide feedback on the new delivery system
while in Leipzig, Germany and stated, "I was very impressed with the accuracy
of the VERITAS system, and appreciated how it improved the ease of delivery
of the SUPERA stent. It represents a truly significant advance and adds
significantly to an outstanding product package."

Commercial availability of the SUPERA VERITAS Transhepatic Biliary System
is planned for the first quarter of 2011.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in interventional radiology, vascular
surgery and cardiology. IDEV's worldwide headquarters is located in Webster,
Texas and its European headquarters is located in Beuningen, The Netherlands.
Please visit www.idevmd.com.

The SUPERA stent is currently indicated in the U.S. for the palliative
treatment of biliary strictures produced by malignant neoplasms and in Europe
for the treatment of biliary strictures produced by malignant neoplasms and
for peripheral vascular use following failed percutaneous transluminal
angioplasty (PTA).

    Contact:    Donna Lucchesi
                Vice President Global Marketing
                IDEV Technologies, Incorporated
                +1-281-525-2000

Donna Lucchesi, Vice President Global Marketing of IDEV Technologies, Incorporated, +1-281-525-2000